Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Boscox is a 100% natural botanical extract developed as an anticoccidial feed additive for livestock and poultry. Its active ingredients, Terminalia gallic acid and costunolide, are extracted from Chinese herbal medicine. Boscox works by selectively inhibiting dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis and nucleotide metabolism of coccidia. This inhibition disables the coccidia during their endogenous developmental stages, including sporozoite, schizogony, and gametogony. Boscox is used to prevent and treat coccidiosis caused by various Eimeria species (such as E. tenella, E. necatrix, E. acervulina, E. maxima, and E. brunetti) in chickens, Isospora coccidiosis in swine, and E. stiedai in rabbits. Additionally, it helps reduce necrotic enteritis caused by Clostridium perfringens and promotes intestinal repair.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Boscox.